Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019...
Cybin (CYBN) Announces Unprecedented Positive Phase 2 Data After Single Dose.
Conference call to discuss CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET
Is There Enough Monkeypox (Mpox) Vaccine to go Around? Maybe yes, More Likely no.
Reported in Gates and Soda
As monkeypox cases continue to mount – topping 31,000 cases globally – governments of...
Armistice Capital Voting on AYTU (AYTU) and Innovus (INNV) Merger.
13D Filing on AYTU (As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner...
Smart for Life (SMFL) Featured by New to the Street
Interviews to Air on National Television Including Bloomberg and Fox Business
MIAMI, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Smart...
Emerald Organic Products, Inc. (EMOR) Announces Exclusive Licensing Agreement With PetVivo Holdings Inc. (PETV).
New York, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. (OTC:EMOR) ("Emerald" or the "Company") is pleased to announce...
Adding ENDRA Life Sciences (NDRA) $0.89 to Watch List.
Another Fatty Liver Idea. This Time a Play on Detecting Fatty Liver Non-Invasively. Heads Up. Nearing Resistance at $0.89.
Citius (CTXR) CEO Myron Holubiak Live on TV, 1:20 Today, June 30th.
VIDEO: Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
That’s it. $225 Million Raised by Atai (ATAI) Gets us Interested in the Psychedelics...
Redefining how the world approaches, prevents, and heals mental health disorders.
LIVE QUOTE
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment...
Latest article
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
